F757 in Hawaii. Pick another state for the same tag.
Against expectation — 2025
Hawaii cites F757 less often than its own record predicts
Versus expected share0.85×
0.85 times the national share — cited less often here than elsewhere.
Share of Hawaii citations0.68%
Of every deficiency written in Hawaii in 2025, this is the portion that was F757.
Hawaii0.68%
National0.80%
Share of all citations that were F757.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What Hawaii surveyors wrote
F757 findings written in Hawaii, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
D · No harm, potential for more than minimal, isolatedMay 1, 2026
Based on interview and record review, the facility failed to ensure that antipsychotic and antidepressant medications received adequate documented behavior monitoring for one of five residents (Resident (R) 5) reviewed for unnecessary medications. This failure placed R5 at risk for ineffective treatment monitoring and continued unnecessary medication use. Findings Include:Review of R5's physician orders revealed R5 is taking Abilify 5 milligrams (mg) one tablet in the evening for depression, trazadone 50mg one tablet at bedtime for depression/anxiety, and vilazodone 10mg two tablets at bedtime for depression. On 04/30/26 at 12:38 PM, an interview was conducted with the Director of Nursing (DON) in training. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction